SALT LAKE CITY, UT / ACCESS Newswire / February 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.305) per share of common stock payable on April 3, 2025 to stockholders of record at the close of business on March 14, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
UTMD's earnings per share (EPS) for the fourth quarter decreased by 27.4% compared to the same period last year, while revenues dropped by 25.8% due to poor sales of PendoTECH products. It is anticipated that revenues will continue to decline in 2025.
Summers Value Partners, an investment management firm, has published its investor letter for the fourth quarter of 2024, which you can download here. The Summers Value Fund LP achieved a net return of 27.4% in 2024, surpassing the 11.3% return of its main benchmark, the Russell 2000 Index ETF (IWM). Additionally, the fund outperformed its secondary benchmark as well.
UTMD's Q4 EPS drops 27.4% year over year, and revenues fall 25.8% on weak PendoTECH sales. Revenues are expected to decline further in 2025.
SALT LAKE CITY, UT / ACCESS Newswire / January 28, 2025 / With Revenues 19% lower, Net Income 17% lower and Earnings Per Share (EPS) 13% lower than in 2023, Utah Medical Products, Inc. (NASDAQ:UTMD) concluded a year of contraction. UTMD's stock price declined 27%, more than twice the EPS decline, which allowed the Company an opportunity to repurchase more than 8% of its shares in the open market.
UTMD has been punished in 2024 despite high-quality business fundamentals and attractive valuation metrics. UTMD's economic characteristics are strong, with high post-tax margins and returns on capital. Projected earnings of $22mm-$31mm by FY'26E, with a valuation range of $67 to $75 per share.
UTMD reports a 5.2% EPS decline in Q3 2024, with revenues declining 20% due to reduced OEM and Filshie sales. Cost controls helped stabilize profit margins.
Utah Medical (UTMD) reports a 19.2% revenue decline in 2Q24, with EPS down 15.3% due to lower sales to major customers. Despite this, profit margins remained stable.
Explore why Zacks rates UTMD with a "Neutral" recommendation, being the first on Wall Street to initiate coverage on the stock. Learn about UTMD's financial stability, diverse product portfolio, and market opportunities, balanced against key challenges in the competitive medical device industry.
Utah Medical Products stock has dropped 14% and is at its lowest point this year due to ongoing lawsuits regarding its Filshie clip system. The lawsuits do pose a risk to UTMD's stock price, and a negative outcome could further impact the company's equity. Despite the risks, UTMD's long-term economics and attractive proposition in multiple markets are bullish features.